Adjuvant Bisphosphonates and Breast Cancer Survival.
Randomized trials have studied bisphosphonates in the adjuvant setting of early breast cancer to investigate their ability to prevent treatment-induced bone loss. Trial results have also suggested their potential to prevent disease recurrence and metastases. These trials are summarized in this review. A recent patient-level meta-analysis by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) finds convincing evidence that adjuvant antiresorptive treatments provide persistent benefits to breast cancer patients in low-estrogen situations and should be considered an important part of the treatment algorithm.
Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, Austria; email: michael.gnant@meduniwien.ac.at.
Stephanie
S
Strobl
Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, Austria; email: michael.gnant@meduniwien.ac.at.
Belgin
B
Korkmaz
Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, Austria; email: michael.gnant@meduniwien.ac.at.
Yelena
Y
Devyatko
Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, Austria; email: michael.gnant@meduniwien.ac.at.
Michael
M
Schuetz
Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, Austria; email: michael.gnant@meduniwien.ac.at.
Ruth
R
Exner
Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, Austria; email: michael.gnant@meduniwien.ac.at.
Peter C
PC
Dubsky
Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, Austria; email: michael.gnant@meduniwien.ac.at.
Raimund
R
Jakesz
Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, Austria; email: michael.gnant@meduniwien.ac.at.
Michael
M
Gnant
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D001853:Bone Marrow; D001859:Bone Neoplasms / Q000517:prevention & control* / Q000556:secondary; D001842:Bone and Bones / Q000503:physiopathology; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017024:Chemotherapy, Adjuvant / Q000379:methods; D004164:Diphosphonates / Q000008:administration & dosage*; D004967:Estrogens / Q000097:blood; D005260:Female; D006801:Humans; D015996:Survival Rate; D059016:Tumor Microenvironment
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D004967:Estrogens
adjuvant therapy; antitumor effect; bone loss; dormant tumor cells; postmenopause